BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19473751)

  • 21. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study.
    Moncada I; Krishnappa P; Romero J; Torremade J; Fraile A; Martinez-Salamanca JI; Porst H; Levine L
    BJU Int; 2019 Apr; 123(4):694-702. PubMed ID: 30365247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute phase Peyronie's disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation.
    Martínez-Salamanca JI; Egui A; Moncada I; Minaya J; Ballesteros CM; Del Portillo L; Sola I; Carballido J
    J Sex Med; 2014 Feb; 11(2):506-15. PubMed ID: 24261900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease.
    Safarinejad MR; Asgari MA; Hosseini SY; Dadkhah F
    BJU Int; 2010 Jul; 106(2):240-8. PubMed ID: 19863517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis.
    Spirito L; Manfredi C; La Rocca R; Napolitano L; Preto M; Di Girolamo A; Arcaniolo D; De Sio M; Creta M; Longo N
    Int J Impot Res; 2024 Apr; 36(2):135-139. PubMed ID: 36788352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Extracorporeal shock-wave therapy in Peyronie's disease].
    Aboian IA; Mitusov VV; Pakus OI; Grachev SV; Pavlov SV; Shestel' AN
    Urologiia; 2004; (5):39-42. PubMed ID: 15560161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term experiences with high-energy shock wave therapy in the management chronic phase Peyronie's disease using two different electromagnetic lithotripters.
    Rassweiler JJ; Scheitlin W; Goezen AS; Radecke F
    World J Urol; 2024 Mar; 42(1):124. PubMed ID: 38453751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach.
    Hauck EW; Altinkilic BM; Ludwig M; Lüdecke G; Schroeder-Printzen I; Arens C; Weidner W
    Eur Urol; 2000 Dec; 38(6):663-9;discussion 670. PubMed ID: 11111181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease.
    Gao L; Qian S; Tang Z; Li J; Yuan J
    Int J Impot Res; 2016 Sep; 28(5):161-6. PubMed ID: 27250868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Peyronie's disease: ultrasonographic follow-up of ESWT].
    Colombo F; Nicola M
    Arch Ital Urol Androl; 2000 Dec; 72(4):388-91. PubMed ID: 11221077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience.
    Husain J; Lynn NN; Jones DK; Collins GN; O'Reilly PH
    BJU Int; 2000 Sep; 86(4):466-8. PubMed ID: 10971273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study.
    Skolarikos A; Alargof E; Rigas A; Deliveliotis Ch; Konstantinidis E
    J Endourol; 2005; 19(1):11-4. PubMed ID: 15735375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction-A Double-Blinded, Sham-Controlled, Randomized Clinical Trial.
    Fojecki GL; Tiessen S; Osther PJ
    J Sex Med; 2017 Jan; 14(1):106-112. PubMed ID: 27938990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Testosterone Concentration Influences the Response to Extracorporeal Shock Wave Treatment in Men With Peyronie's Disease.
    Dell'Atti L; Slyusar V; Ronchi P
    Urology; 2024 Jan; 183():111-116. PubMed ID: 37832829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients.
    Porst H
    Sex Med Rev; 2021 Jan; 9(1):93-122. PubMed ID: 32499189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis.
    Cocci A; Cito G; Urzì D; Minervini A; Di Maida F; Sessa F; Mari A; Campi R; Falcone M; Capece M; Morelli G; Cacciamani G; Rizzo M; Polito C; Giammusso B; Morgia G; Verze P; Salonia A; Cai T; Mirone V; Mondaini N; Russo GI
    J Sex Med; 2018 Oct; 15(10):1472-1477. PubMed ID: 30245025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies.
    Lipshultz LI; Goldstein I; Seftel AD; Kaufman GJ; Smith TM; Tursi JP; Burnett AL
    BJU Int; 2015 Oct; 116(4):650-6. PubMed ID: 25711400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.
    Chung E
    Korean J Urol; 2015 Nov; 56(11):775-80. PubMed ID: 26568796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter Prospective Study of Grafting With Collagen Fleece TachoSil in Patients With Peyronie's Disease.
    Fernández-Pascual E; Manfredi C; Torremadé J; Ibarra FP; Geli JS; Romero-Otero J; García-Baquero R; Poblador AF; Barbará MR; Campos-Juanatey F; Rojo AE; Iribarren IM; Rodríguez JC; Martínez-Salamanca JI
    J Sex Med; 2020 Nov; 17(11):2279-2286. PubMed ID: 32830078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial.
    Ziegelmann M; Savage J; Toussi A; Alom M; Yang D; Kohler T; Trost L
    J Urol; 2019 Sep; 202(3):599-610. PubMed ID: 30916626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis.
    Wang X; Liu H; Tang G; Wu G; Chu Y; Wu J; Cui Y
    BMC Urol; 2023 Sep; 23(1):145. PubMed ID: 37700253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.